Euthyroid Hyperthyroxinemia Clinical Presentation

  • Author: Reetu Singh, MD; Chief Editor: George T Griffing, MD   more...
 
Updated: Nov 28, 2011
 

History

Patients with euthyroid hyperthyroxinemia usually are asymptomatic. However, some patients affected with thyroid hormone resistance may present with the symptoms of hypothyroidism or hyperthyroidism, as follows:

  • Symptoms of hypothyroidism may include the following:
    • Growth retardation
    • Delayed bone maturation
    • Learning disabilities
    • Mental retardation
    • Sensorineural deafness
  • Symptoms of hyperthyroidism may include the following:
    • Typical symptoms - Absent
    • Children with thyroid hormone resistance - May had attention deficit hyperactivity disorder.[5]

A history of drug intake may include the following[6] :

  • Oral contraceptives or estrogen replacement[7]
  • Amiodarone
  • Propranolol[8]
  • Heparin
  • Perphenazine
  • Clofibrate
  • 5-fluorouracil

A history of drug abuse may include the following:

  • Heroin
  • Methadone treatment

The patient's menstrual history may include the following:

  • Amenorrhea (pregnancy)
  • Delayed puberty (thyroid hormone resistance)

A history of chronic diseases may include the following:

  • Liver diseases - Active hepatitis, chronic hepatitis, biliary cirrhosis
  • Human immunodeficiency virus (HIV) infection[9]
  • Acute intermittent porphyria
  • Malignant diseases - Islet cell tumors and glucagonomas

A history of psychiatric conditions may include acute psychosis.

The patient's family history is an important aspect of diagnosis, because one of the most revealing clues in the diagnosis of hereditary conditions is the discovery of another family member with the same laboratory abnormalities.

Next

Physical

Patients with euthyroid hyperthyroxinemia do not manifest any physical signs other than those pertinent to their underlying pathology. Thyroid hormone resistance signs include the following:

  • Goiter
  • Nystagmus
  • Tachycardia
  • Increased metabolic rate
  • Deafness

Liver disease signs include the following:

  • Icterus
  • Hepatomegaly
Previous
Next

Causes

Many conditions can cause elevated levels of thyroid hormones in patients with no clinical evidence of hyperthyroidism.[1] These conditions may be grouped as follows:

  • Physiologic conditions
    • The most common physiologic condition resulting in elevated TBG concentrations is a normal pregnancy.[10]
    • Estrogens stimulate the production of TBG by the liver and increase the glycosylation of TBG, which reduces its clearance. As a result, the total T4 and T3 are elevated, but T3 resin uptake is decreased, resulting in normal free T4 and T3 levels.
    • In newborns, the increased TBG most likely is due to the transplacental transfer of estrogens.[11]
  • Hereditary causes - Several inherited abnormalities of thyroid hormone–binding proteins are now recognized, as follows[12, 13, 14] :
    • Increased TBG
      • Hereditary TBG excess is an X-linked disorder that results in increased synthesis of TBG, with normal immunoreactivity and binding affinity for thyroid hormones.[15]
      • Because TBG has a high affinity for T4 and T3, the total concentrations of both hormones are elevated.
      • The diagnosis can be made by direct measurement of TBG by radioimmunoassay.
    • Increased TBPA[16]
      • Euthyroid hyperthyroxinemia due to hereditary TBPA excess has also been described.
      • Because TBPA carries T4 far more often than it does T3, the T3 resin uptake does not help in the detection of this condition. A falsely elevated free T4 index results from this condition; however, free T4 levels measured by radioimmunoassay or equilibrium dialysis are normal.
    • FDH[17]
      • FDH is a genetic disorder that occurs primarily in Hispanic people.
      • This condition is characterized by the presence of a mutant form of albumin, which is produced by an Arg-His substitution at codon 218.[18] This form of albumin has an increased affinity for T4 but not for T3. The increased binding of T4 results in normal T3 resin uptake but an elevated free T4 index. In patients with FDH, the serum thyroid-stimulating hormone (TSH) level, total T3 level, and free T3 index are normal.
      • This mutation is seen in white persons; however, in the Japanese family in which this condition was found, the mutation at codon 218 resulted in an Arg-Pro substitution.[3]
      • The diagnosis can be established by performing a resin uptake with radiolabeled T4 instead of T3. Alternatively, the serum T4 and free T4 index can be measured in family members, because this is an autosomal dominant condition.
      • Free T4 levels are normal when measured by equilibrium dialysis; in contrast, the free T4 hormone may be falsely elevated in a radioimmunoassay. The abnormal albumin level can be demonstrated by thyroid hormone–binding protein electrophoresis.[19, 20]
      • In another albumin variant, described in a Thai family, the albumin had a markedly increased affinity for T3 only. The condition was called familial dysalbuminemic hypertriiodothyroninemia.
  • Drugs causing hyperthyroxinemia[6]
    • Estrogenic preparations increase the production of TBG and reduce its clearance (see the above list of physiologic conditions). Heroin, methadone, clofibrate, perphenazine, and 5-fluorouracil also raise the levels of serum TBG by increasing its secretion by the liver.
    • Amiodarone, iopanoic acid, and ipodate block the conversion of T4 into T3, causing an elevation of T4; they also reverse T3, resulting in a decreased T3 level. In addition, these drugs may cause an elevation of TSH, which also is due to their inhibition of the conversion of T4 into T3 in the central nervous system, thereby interfering with the feedback regulation of pituitary thyrotropin secretion.[21] Because of the escape phenomenon, however, the effect is transient (lasting a few months).
    • Heparin, even when administered subcutaneously, may cause an increase in serum free T4 levels. This results from the stimulation of lipoprotein lipase by heparin, which generates free fatty acids. These fatty acids inhibit the binding of T4 to TBG.
    • Propranolol also inhibits extrathyroidal conversion of T4 into T3.[8]
  • Thyroid hormone resistance syndrome[17]
    • In compensated generalized thyroid hormone resistance, the total and the free T4 and T3 levels are elevated, with normal or slightly elevated TSH levels in the absence of any signs of hyperthyroidism. The inheritance usually is autosomal dominant, but it can be recessive in 10% of the cases.
    • Most patients are euthyroid, but some may have goiter, stunted growth, delayed menstruation, hyperactivity disorders, and resting tachycardia.[5]
    • The defect has been postulated to lie in the postreceptor processes, in the nonnuclear T3 receptors, or in qualitative abnormalities of nuclear T3 receptors.
  • Hyperthyroxinemia of systemic illness
    • In most patients with systemic illness, the total and free serum T3 levels are reduced because of decreased peripheral deiodination of T4 into T3 (due to the inhibition of 5'-deiodinase). This results in a modest increase in the serum total T4 concentration, which may occur in 2% of patients who are acutely ill and in some patients with hyperemesis gravidarum.
    • Liver diseases (eg, acute infectious hepatitis, chronic active hepatitis, primary biliary cirrhosis) produce high levels of TBG from increased production and reduced clearance, the result of functional hyperestrogenemia. Estrogen-secreting tumors, acute intermittent porphyria, and HIV also result in increased TBG levels due to enhanced liver production.
    • Acute psychosis causes a modest elevation of total and free serum T4 concentrations in 1-10% of patients. Although the actual mechanism is unknown, it has been postulated that central activation of the hypothalamic-pituitary axis contributes to the abnormality. The elevation usually is transient and resolves in several weeks.
    • Increased TBPA also has been reported in patients with glucagonoma and islet cell carcinomas.
  • Miscellaneous
    • The presence of anti-T4 immunoglobulins can cause a spuriously elevated level of total T4 when T4 is measured by radioimmunoassay. These immunoglobulins also bind radiolabeled T4, thereby preventing it from binding to the anti-T4 antibodies used in the assay; this results in a high serum total T4 value. Because these antibodies do not bind to T3, the thyroid hormone–binding ratio, as estimated by the T3 uptake, is normal. They can be detected by adding radiolabeled T4 to the patient's serum and precipitating the immunoglobulin fraction with polyethylene glycol.
    • Anti-T3 immunoglobulins can lead to a falsely high total T3 level.
    • Through a mechanism that is not yet clear, extremely high altitudes can cause similar biochemical abnormalities in thyroid function.
Previous
 
 
Contributor Information and Disclosures
Author

Reetu Singh, MD  Fellow, Department of Internal Medicine, Beebe Medical Center

Reetu Singh, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Thyroid Association, and Endocrine Society

Disclosure: Nothing to disclose.

Coauthor(s)

Serge A Jabbour, MD  Associate Professor, Department of Medicine, Division of Endocrinology, Thomas Jefferson University

Serge A Jabbour, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, American Thyroid Association, Endocrine Society, and Pennsylvania Medical Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Steven R Gambert, MD  Professor of Medicine, Johns Hopkins University School of Medicine; Director of Geriatric Medicine, University of Maryland Medical Center and R. Adams Cowley Shock Trauma Center

Steven R Gambert, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physician Executives, American College of Physicians, American Geriatrics Society, Association of Professors of Medicine, Endocrine Society, and Gerontological Society of America

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Romesh Khardori, MD, PhD, FACP  Professor of Endocrinology, Director of Training Program, Division of Endocrinology, Diabetes and Metabolism, Strelitz Diabetes and Endocrine Disorders Institute, Department of Internal Medicine, Eastern Virginia Medical School

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, and Endocrine Society

Disclosure: Nothing to disclose.

Mark Cooper, MBBS, PhD, FRACP  Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD  Professor of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

References
  1. Borst GC, Eil C, Burman KD. Euthyroid hyperthyroxinemia. Ann Intern Med. Mar 1983;98(3):366-78. [Medline].

  2. Tang KT, Yang HJ, Choo KB, et al. A point mutation in the albumin gene in a Chinese patient with familial dysalbuminemic hyperthyroxinemia. Eur J Endocrinol. Oct 1999;141(4):374-8. [Medline]. [Full Text].

  3. Wada N, Chiba H, Shimizu C, et al. A novel missense mutation in codon 218 of the albumin gene in a distinct phenotype of familial dysalbuminemic hyperthyroxinemia in a Japanese kindred. J Clin Endocrinol Metab. Oct 1997;82(10):3246-50. [Medline]. [Full Text].

  4. Yeap BB, Alfonso H, Chubb SA, Walsh JP, Hankey GJ, Almeida OP, et al. Higher free thyroxine levels are associated with frailty in older men. The Health In Men Study. Clin Endocrinol (Oxf). Nov 11 2011;[Medline].

  5. Millichap JG. Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics. Feb 2008;121(2):e358-65. [Medline].

  6. Molashenko NV, Sviridenko NIu, Platonova NM, et al. [The specific features of thyrotoxicosis and euthyroid hyperthyroxinemia developed due to the use of cordarone]. Klin Med (Mosk). 2004;82(12):35-9. [Medline].

  7. Sänger N, Stahlberg S, Manthey T, et al. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use. Contraception. Jun 2008;77(6):420-5. [Medline].

  8. Mooradian A, Morley JE, Simon G, et al. Propranolol-induced hyperthyroxinemia. Arch Intern Med. Nov 1983;143(11):2193-5. [Medline].

  9. Wiener M, Lo Y, Klein R. Abnormal thyroid function in older men with or at risk for HIV infection. HIV Med. Jun 11 2008;[Medline].

  10. Vaidya B, Hubalewska-Dydejczyk A, Laurberg P, Negro R, Vermiglio F, Poppe KG. Treatment and Screening of Hypothyroidism in Pregnancy: Results of a European Survey. Eur J Endocrinol. Oct 24 2011;[Medline].

  11. Kvetny J, Poulsen H. Transient hyperthyroxinemia in newborns from women with autoimmune thyroid disease and raised levels of thyroid peroxidase antibodies. J Matern Fetal Neonatal Med. Dec 2006;19(12):817-22. [Medline].

  12. Moses AC, Rosen HN, Moller DE, et al. A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia. J Clin Invest. Dec 1990;86(6):2025-33. [Medline]. [Full Text].

  13. Hishinuma A, Mochizuki Y, Kasai K, et al. [Thyroxine-binding proteins--familial euthyroid hyperthyroxinemia due to point mutations of transthyretin]. Nippon Rinsho. Apr 1994;52(4):886-9. [Medline].

  14. Magalhães PK, Rodrigues Dare GL, Rodrigues Dos Santos S, et al. Clinical features and genetic analysis of four Brazilian kindreds with resistance to thyroid hormone. Clin Endocrinol (Oxf). Nov 2007;67(5):748-53. [Medline].

  15. Tucker WS Jr. Euthyroid hyperthyroxinemia due to familial excess of thyroxine-binding globulin. South Med J. Mar 1989;82(3):368-71. [Medline].

  16. Maye P, Bisetti A, Burger A, et al. Hyperprealbuminemia, euthyroid hyperthyroxinemia, Zollinger-Ellison-like syndrome and hypercorticism in a pancreatic endocrine tumour. Acta Endocrinol (Copenh). Jan 1989;120(1):87-91. [Medline].

  17. Gharib H, Klee GG. Familial euthyroid hyperthyroxinemia secondary to pituitary and peripheral resistance to thyroid hormones. Mayo Clin Proc. Jan 1985;60(1):9-15. [Medline].

  18. Rushbrook JI, Becker E, Schussler GC, et al. Identification of a human serum albumin species associated with familial dysalbuminemic hyperthyroxinemia. J Clin Endocrinol Metab. Feb 1995;80(2):461-7. [Medline]. [Full Text].

  19. Eber O, Langsteger W, Florian W, et al. [Evaluating thyroid gland function in patients with protein anomalies]. Acta Med Austriaca. 1991;18(1):11-9. [Medline].

  20. George PM, Sheat JM, Palmer BN. Detection of protein binding abnormalities in euthyroid hyperthyroxinemia. Clin Chem. Sep 1988;34(9):1745-8. [Medline]. [Full Text].

  21. Jackson JA, Verdonk CA, Spiekerman AM. Euthyroid hyperthyroxinemia and inappropriate secretion of thyrotropin. Recognition and diagnosis. Arch Intern Med. Jul 1987;147(7):1311-3. [Medline].

  22. Stockigt JR, Barlow JW. The diagnostic challenge of euthyroid hyperthyroxinemia. Aust N Z J Med. Apr 1985;15(2):277-84. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.